BLOOD VISCOSITY AND GIT DISORDERS OF HCV PATIENTS
Downloads
Background: Hepatitis C virus (HCV) infection is a blood-borne viral illness responsible for significant morbidity and mortality all over the world. The current study aims to determine the role of HCV in increasing blood viscosity that is accompanied by attacks and serious heart disorders, in addition to knowing the effect of this infection on irritations and disorders of the digestive system. Methods: The practical side included collecting blood samples from 50 HCV infected persons and 50 healthy persons as a control group. Laboratory and clinical tests were carried out at Al-Diwaniyah General Teaching Hospital, where HCV was determined by checking for antibodies using the ELISA test, while blood viscosity was determined by knowing the percentage of red blood cells (hemocrit) as part of the complete blood test. Gastrointestinal tract (GIT) diseases were diagnosed using gastroendoscopy and x-rays, in addition to investigations Helicobacter pylori (H. pylori). Result: ulcers and stomach acidity with colitis together (A,B,D) were in high rates in patients (58%) compared with healthy people (6%) and produced this is a clear statistical difference (p<0.05). Moreover, Blood viscosity increased (71.54%) with a rise titer of HCV in patients blood (18.38 logIU/mL) that associated with appearance of strong positive linear correlation (r= 0.965, p= 0.004). In conclusion: HCV leads to serious complications, especially the digestive system and circulation, and the risk of these disorders increases with the increased survival of the virus C in the patient's liver. Therefore, it is necessary to use appropriate treatments, especially effective modern treatments represented by Harvoni.
Wong RJ, Kanwal F, Younossi ZM, et al. Hepatitis C virus infection and coronary artery disease risk: A systematic review of the literature. Digestive Diseases and Sciences. 2014;59:1586-1593.
Hsu YC, Ho HJ, Huang YT, et al. Association between antiviral treatment and extrahepatic outcomes in patients with hepatitis C virus infection. Gut. 2015;64:495-503.
Gill K, Ghazinian H, Manch R, Gish R. Hepatitis C virus as a systemic disease: Reaching beyond the liver. Hepatology International. 2016;10:415-423.
Domont F and Cacoub P. Chronic hepatitis C virus infection, a new cardiovascular risk factor? Liver International. 2016;36:621.
Trepo C. A brief history of hepatitis milestones. Liver International. 2014; (34):29–37.
Ayoub HH, Al Kanaani Z, Abu-Raddad LJ, et al. Characterizing the temporal evolution of the hepatitis C virus epidemic in Pakistan. J. Viral Hepat. 2018; 25 (6):670-679.
McCombs J, Matsuda T, Tonnu-Mihara I, et al. The risk of long-term morbidity and mortality in patients with chronic hepatitis C: results from an analysis of data from a department of veterans affairs clinical registry. JAMA Internal Medicine, 2014.174(2):204–212.
Al Kanaani Z, Mahmud S, Kouyoumjian SP, et al. The epidemiology of hepatitis C virus in Pakistan: systematic review and meta-analyses. R. Soc. Open Sci. 2018. 5 (4): 180257.
Dedania B and Wu GY. Dermatologic extrahepatic manifestations of hepatitis C. Journal of Clinical and Translational Hepatology. 2015;3:127-133.
Tang L, Marcell L, Kottilil S. Systemic manifestations of hepatitis C infection. Infectious Agents and Cancer. 2016;11:29.
Cacoub P, Comarmond C, Domont F, et al. Extrahepatic manifestation of chronic hepatitis C virus infection. Therapeutic Advances in Infectious Disease. 2016;3:3-14.
Cornu R, Béduneau A, Martin H. Influence of nanoparticles on liver tissue and hepatic functions: A review. Toxicology. 2020; 30(430):152344.
Modrzynska J, Berthing T, Ravn-Haren G, et al. Primary genotoxicity in the liver following pulmonary exposure to carbon black nanoparticles in mice. Part Fibre Toxicol. 2018 Jan 3;15(1):2.
Hodowanec AC, Lee RD, Brady KE, Gao W, Kincaid S, Plants J, Bahk M, Mackman N, Landay AL, Huhn GD. A matched cross-sectional study of the association between circulating tissue factor activity, immune activation and advanced liver fibrosis in hepatitis C infection. BMC Infect Dis. 2015; 15: 190.
Tana MM, Zhao X, Bradshaw A, Moon MS, Page S, Turner T, Rivera E, Kleiner DE, Heller T. Factors associated with the platelet count in patients with chronic hepatitis C. Thromb Res. 2015; 135: 823-828.
Zhou WC, Zhang QB, Qiao L. Pathogenesis of liver cirrhosis. World J Gastroenterol. 2014; 20: 7312-7324
González-Reimers E, Quintero-Platt G, Martín-González C, et al. Thrombin activation and liver inflammation in advanced Hepatitis C virus infection. World J Gastroenterol 2016. 14; 22(18): 4427-4437.
Asaduzzaman M, Bappy SR, Fatema B, et al. Effect of Hepatitis C Virus (HCV) on Hemoglobin, Blood Cells and Random Blood Glucose Levels among Serologically Positive HCV Patients. IOSR Journal of Nursing and Health Science (IOSR-JNHS). 2017; 5(1):41-45.
Di Bisceglie AM, Axiotis CA, Hoofnagle JH, Bacon BR. Measurements of iron status in patients with chronic hepatitis. Gastroenterology. 1992;102(6):2108-13.
Karasu Z, Tekin F, Ersoz G, et al. Liver fibrosis is associated with decreased Peripheral platelet count in patients with chronic hepatitis B and C. Digestive diseases and sciences. 2007; 52(6):1535-1539.
El Barbary M A, Saad AE, Attia FM, et al. Thrombocytopenia in patients with chronic hepatitis C: a possible role of hcv on platelet progenitor cell maturation. Angiology. 2010;61(3):304–313.
Kauf TL, Nelson D R, Schelfhout J, et al. Trends in the prevalence of thrombocytopenia among individuals iInfected with hepatitis C Virus in the United States, 1999–2008. BMC Research Notes. 2012;5: 142.
Tsai MC, Kee KM, Chen YD, et al. Excess mortality of hepatocellular carcinoma and morbidity of liver cirrhosis and hepatitis in HCV-endemic areas in an HBV-endemic country: geographic variations among 502 villages in southern Taiwan. Journal of Gastroenterology and Hepatology (Australia). 2007;22(1):92–98.
Giannini E, Botta F, Borro P, et al. Relationship between thrombopoietin serum levels and liver function in patients with chronic liver disease related to hepatitis C virus infection. The American Journal of Gastroenterology. 2003;98(11):2516–2520.
Tsai M-H, Lin K-H, Lin K-T, et al. Predictors for Early Identification of Hepatitis C Virus Infection. BioMed Research International. 2015. 429290: 1-7.
Hobisch-Hagen P, Jelkmann W, Mayr A, et al. Low platelet count and elevated serum thrombopoietin after severe trauma. European Journal of Haematology. 2000;64(3):157–163.
Alsaran KA, Sabry AA, Alghareeb AH, et al. Effect of Hepatitis C Virus on Hemoglobin and Hematocrit Levels in Saudi Hemodialysis Patients. Renal Failure. 2009. 31:5.
Sabry A, El-Dahshan K, Mahmoud K, et al. Effects of hepatitis C virus infection on hematocrit and hemoglobin levels in Egyptian hemodialysis patients. Eur J Gen Med. 2007; 4(1)9–15.
Zullo A, Rinaldi V, Meddi P, et al. Helicobacter pylori infection inDyspeptic cirrhotic patients. Hepatogastro-enterology 1999;46:395-400.
Kitano S and Dolgor B. Does portal hypertension contribute to thePathogenesis of gastric ulcer associated with liver cirrhosis?. J Gastroenterol. 2000;35:79-86.
Dore MP, Mura D, Deledda S, et al. Active peptic ulcer disease in patients with Hepatitis C virus-related cirrhosis: The role of Helicobacter pylori infection And portal hypertensive gastropathy. Can J Gastroenterol. 2004. 18(8):1-5.
El-Masry S, El-Shahat M, Badra G, et al. Helicobacter pylori and Hepatitis C Virus Coinfection in Egyptian Patients. Journal of Global Infectious Diseases. 2010. 2 (1):1-6.
Pellicano R, Leone N, Berrutti M, et al. Helicobacter pylori seroprevalence in hepatitis C virus positive patients with cirrhosis. J Hepatol. 2000;33:648–50.
Ponzetto A, Pellicano R, Leone N, et al. Helicobacter infection and cirrhosis in hepatitis C virus carriage: Is it an innocent bystander or a troublemaker?. Med Hypotheses. 2000;54:275–7.
Copyright (c) 2024 Nawras Najah Mubark, Rasha Ibrahim Salman, Shahad Q. Al-Hamadiny
This work is licensed under a Creative Commons Attribution 4.0 International License.
